Full-Time

Associate Director / Director

Head & Neck Oncology Lifecycle Management

Posted on 4/5/2025

Natera

Natera

1,001-5,000 employees

Genetic testing and diagnostics solutions provider

Compensation Overview

$168.2k - $245.2k/yr

Expert

Company Historically Provides H1B Sponsorship

Remote in USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Market Research
Requirements
  • Bachelor’s degree, Advanced degree preferred (MBA or PhD)
  • Head and Neck oncology market experience strongly preferred
  • >10 years experience in product marketing, market analytics at a pharmaceutical / biotech company
  • Previous KOL management experience preferred
  • Working knowledge of oncology molecular testing / biomarkers
  • ~25% travel required (advisory boards, congresses, sales / marketing meetings, customer meetings)
Responsibilities
  • Own the lifecycle planning and success of Head & Neck cancer, collaborating with cross-functional teams to develop and execute a strategic plan that drives usage, awareness, and advocacy across key stakeholders worldwide.
  • Lead Head & Neck cancer lifecycle team that is a cross-functional team accountable for progress on tumor goals and deploying resources to maximize outcomes.
  • Establish tumor-specific goals to be owned by the lifecycle team and across functions.
  • Serve as a critical member on clinical / medical teams, helping define and prioritize key indications while identifying and addressing evidence gaps.
  • Serve as a critical member on commercial subteams, helping to maximize Natera potential by escalating and addressing critical barriers that limit commercial adoption.
  • Maintain a deep expertise in the Head and Neck cancer space by integrating real-time customer insights, publications, data presentations, competitive and market intelligence.
  • Drive market access efforts, leading the development of reimbursement dossiers for Medicare/MolDx and commercial payers to secure coverage for non-covered indications.
  • Develop and execute KOL engagement strategies, collaborating with marketing and medical teams to gather insights, build relationships, and foster advocacy.
  • Shape the value proposition for Natera’s oncology products in collaboration with Medical Affairs and Commercial Marketing, leveraging clinical evidence and market dynamics.
  • Co-lead advisory boards and market research efforts in partnership with Medical Affairs.
  • Regularly present strategic plans and progress to executive leadership.
Desired Qualifications
  • Ability to lead without authority, influence and inspire individuals
  • Proven strategic agility with an enterprise mindset and ability to operate with executive presence
  • Ability to partner and collaborate across a broad range of internal and external partners
  • Strong customer orientation and focus, particularly establishing thought leader relationships
  • Proven ability to communicate the complex simply (biomarkers, multiple indications, etc.)
  • Strong organizational / time management skills; manage and complete multiple projects

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and monitor organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care through precise genetic insights.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Austin, Texas

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Rising demand for personalized medicine supports Natera's genetic testing services.
  • The global NIPT market is expected to reach $7.3 billion by 2025.
  • Increased adoption of liquid biopsy tests aligns with Natera's cfDNA focus.

What critics are saying

  • Expansion into new Austin space could strain financial resources.
  • Increased competition from companies like Lantheus Holdings threatens market share.
  • HEROES trial for breast cancer may face regulatory hurdles or delays.

What makes Natera unique

  • Natera specializes in cell-free DNA testing for diverse medical applications.
  • Their Signatera test offers personalized ctDNA analysis for cancer patients.
  • Natera's Panorama NIPT has conducted over 2 million non-invasive prenatal tests.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↓ -1%

2 year growth

↑ 5%
PRWeb
May 30th, 2025
The Melanoma Research Foundation To Host The Denver Miles For Melanoma 5K

The Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, supporters, care partners and thrivers. This year we will be hosting our annual Denver event on Saturday, June 14, 2025 at Sloan Lake Park at 7:30 AM MT. Opening Ceremonies will start at 8:30 AM MT and our race will kick off promptly at 9:00 AM MT. We are excited to share that Kyle Speller, PA Announcer for the Denver Nuggets, will be returning as our emcee on event day! We're also excited to welcome back local sponsor, Cara Mia Dermatology, who will be providing free on-site skin screenings—helping our community stay sun-safe while supporting a great cause.DENVER, May 29, 2025 /PRNewswire-PRWeb/ -- The Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, supporters, care partners and thrivers. This year we will be hosting our annual Denver event on Saturday, June 14, 2025 at Sloan Lake Park at 7:30 AM MT. Opening Ceremonies will start at 8:30 AM MT and our race will kick off promptly at 9:00 AM MT

Intelligence360
May 15th, 2025
Natera To Spend $9.9 Million To Occupy 30,000 Square Feet Of Space In Austin Texas.

Natera to spend $9.9 Million to occupy 30,000 square feet of space in Austin Texas. Natera to spend $9.9 Million to occupy 30,000 square feet of space in Austin Texas.Austin, Texas — According to state and local development sources, Natera plans to invest $9,900,000.00 to build out 30,000 square feet of new space in Austin. The company plans to occupy the new space at 13011A McCallen Pass in Austin, on or about January 1, 2026. According to the company website Natera is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, womens health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives. Where some set out to build a test, we set out to achieve a mission: change the management of disease worldwide by using DNA testing to proactively inform treatment

TXBN
Apr 24th, 2025
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera(TM) Genome MRD Test

Natera announces broad clinical launch of ultra-sensitive signatera(tm) genome MRD test.

Slater Sentinel
Apr 3rd, 2025
DnB Asset Management AS Invests $235,000 in Natera, Inc. (NASDAQ:NTRA)

DnB Asset Management AS invests $235,000 in Natera, Inc. (NASDAQ:NTRA).

TXBN
Mar 25th, 2025
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

AUSTIN, Texas - (BUSINESS WIRE) - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting on April 29, 2025.

INACTIVE